A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia Article
Full Text via DOI: 10.1038/s41408-021-00568-3
Web of Science: 000712956600001
Open Access
International Collaboration